• 1
    Doong SL, Tsai CH, Schinazi RF, Liotta DC, Cheng YC. Inhibition of the replication of hepatitis B virus in vitro by 2′, 3′-dideoxy-3′-thiacytidine and related analogues. Proc Natl Acad Sci U S A 1991; 88:84958499. MEDLINE
  • 2
    Tyrrell DLJ, Mitchell MC, De Man RA, Schalm SW, Main J, Thomas HC, Fevery J, et al. Phase II trial of lamivudine for chronic hepatitis B [Abstract]. Hepatology 1993; 18(Suppl):112A.
  • 3
    Dienstag JL, Perrillo RP, Schiff ER, Bartholomew M, Vicary C, Rubin M. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 1995; 333:16571661. MEDLINE
  • 4
    Nevens F, Main J, Honkoop P, Tyrrell DL, Barber J, Sullivan MT, Fevery J, et al. Lamivudine therapy for chronic hepatitis B: a six-month randomized dose-ranging study. Gastroenterology 1997; 113:12581263. MEDLINE
  • 5
    Lai C-L, Chien R-N, Leung N, Chang T-T, Guan R, Tai D-I, Ng K-Y, et al. A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998; 339:6168. MEDLINE
  • 6
    Gao Q, Gu Z, Parniak MA, Cameron J, Cammack N, Boucher C, Wainberg MA. The same mutation that encodes low-level human immunodeficiency virus type 1 resistance to 2′, 3′-dideoxyinosine and 2′, 3′-dideoxycitidine confers high-level resistance to the (−) enantiomer of 2′, 3′-dideoxy-3′-thiacytidine. Antimicrob Agents Chemother 1993; 37:13901392. MEDLINE
  • 7
    Boucher CAB, Cammack N, Schipper P, Schuurman R, Rouse P, Wainberg MA, Cameron J. High-level resistance to (−) enantiomeric 2′, 3′-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother 1993; 37:22312234. MEDLINE
  • 8
    Tisdale M, Kemp SD, Parry NR, Larder BS. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc Natl Acad Sci U S A 1993; 90:56535656. MEDLINE
  • 9
    Schuurman R, Nijhuis M, van Leeuwen R, Schipper P, de Jong D, Collis P, Danner SA, et al. Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). J Infect Dis 1995; 171:14111419. MEDLINE
  • 10
    Allen MI, Deslauriers M, Andrews CW, Tipples GA, Walters K-A, Tyrrell DLJ, Brown N, et al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Hepatology 1998; 27:16701677. MEDLINE
  • 11
    Jansen RW, Johnson LC, Averett DR. High-capacity in vitro assessment of anti-hepatitis B virus compound selectivity by a virion-specific polymerase chain reaction assay. Antimicrob Agents Chemother 1993; 37:441447. MEDLINE
  • 12
    Carman WF, Jacyna MR, Hadziyannis S, Karayiannis P, McGarvey MJ, Makris A, Thomas HC. Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. Lancet 1989; 2:588591. MEDLINE
  • 13
    Honkoop P, De Man RA, Heitjink RA, Schalm SW. Hepatitis B reactivation after lamivudine. Lancet 1995; 346:11561157. MEDLINE
  • 14
    Wong DKH, Cheung AM, O'Rourke K, Naylor CD, Detsky AS, Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B: a meta-analysis. Ann Intern Med 1993; 119:312323. MEDLINE
  • 15
    Heathcote J, Schalm SW, Cianciara J, Farrell G, Feinmann V, Shermann M, Dhillon A P, Moorat AE, et al. Lamivudine and Intron A combination treatment in patients with chronic hepatitis B infection [Abstract]. J Hepatol 1998; 28(Suppl 1):43.
  • 16
    Hoofnagle JH, Di Bisceglie AM, Waggoner JG, Park Y. Interferon alfa for patients with clinically apparent cirrhosis due to chronic hepatitis B. Gastroenterology 1993; 104:11161121. MEDLINE
  • 17
    Perrillo R, Tamburro C, Regenstein F, Balart L, Bodenheimer H, Silva M, Schiff E, et al. Low-dose, titratable interferon alfa in decompensated liver disease caused by chronic infection with hepatitis B virus. Gastroenterology 1995; 109:908916. MEDLINE
  • 18
    Wainberg MA, Drosopoulos WC, Salomon H, Hsu M, Borkow G, Parniak MA, Gu Z, et al. Enhanced fidelity of 3TC-selected mutant HIV-1 reverse transcriptase. Science 1996; 271:12821285. MEDLINE
  • 19
    Melegari M, Scaglioni PP, Wands JR. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective. Hepatology 1998; 27:628633. MEDLINE
  • 20
    Eleftheriou N, Thomas HC, Heathcote J, Sherlock S. Incidence and clinical significance of e antigen and antibody in acute and chronic liver disease. Lancet 1975; 2:11711173. MEDLINE
  • 21
    Nordenfelt E, Andren-Sandberg M. Dane particle-associated DNA polymerase and e antigen: relation to chronic hepatitis among carriers of hepatitis B surface antigen. J Infect Dis 1976; 134:8589. MEDLINE
  • 22
    Hoofnagle JH, Dusheiko GM, Seeff LB, Jones EA, Waggoner JG, Bales ZB. Seroconversion from hepatitis B e antigen to antibody in chronic type B hepatitis. Ann Intern Med 1981; 94:744748. MEDLINE
  • 23
    Fattovich G, Rugge M, Brollo L, Pontisso P, Noventa F, Guido M, Alberti A, et al. Clinical, virologic and histologic outcome following seroconversion from HBeAg to anti-HBe in chronic hepatitis type B. Hepatology 1986; 6:167172. MEDLINE
  • 24
    Alberti A, Pontisso P, Fattovich G, Schiavon E, Chemello L, Bortolotti F, Tremolada F, et al. Changes in serum hepatitis B virus (HBV) DNA positivity in chronic HBV infection: results of a long-term follow-up study of 138 patients. J Infect Dis 1986; 154:562569. MEDLINE
  • 25
    Scullard GH, Andres LL, Greenberg HB, Smith JL, Sawhney VK, Neal EA, Mahal AS, et al. Antiviral treatment of chronic hepatitis B virus infection: improvement in liver disease with interferon and adenine arabinoside. Hepatology 1981; 1:228232. MEDLINE
  • 26
    Hoofnagle JH, Peters M, Mullen KD, Jones DB, Rustgi V, Di Bisceglie A, Hallahan C, et al. Randomized, controlled trial of recombinant human α-interferon in patients with chronic hepatitis B. Gastroenterology 1988; 95:13181325. MEDLINE
  • 27
    Perrillo RP, Regenstein FG, Peters MG, DeSchryver-Kecskemeti K, Bodicky CJ, Campbell CR, Kuhns MC. Prednisone withdrawal followed by recombinant alpha interferon in the treatment of chronic type B hepatitis: a randomized, controlled trial. Ann Intern Med 1988; 109:95100. MEDLINE
  • 28
    Perrillo RP, Schiff ER, Davis GL, Bodenheimer HCJ, Lindsay K, Payne J, Dienstag JL, et al. A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. N Engl J Med 1990; 323:295301. MEDLINE
  • 29
    Wu PC, Lok ASF, Lau JYN, Lauder IJ, Lai CL. Histologic changes in Chinese patients with chronic hepatitis B virus infection after interferon-α therapy. Am J Clin Pathol 1992; 98:402407. MEDLINE
  • 30
    Honkoop P, De Man RA, Zondervan PE, Niesters HGM, Schalm SW. Histologic improvement in patients with chronic hepatitis B virus infection treated with lamivudine. Liver 1997; 17:103106. MEDLINE
  • 31
    Leung NWY, Lai CL, Liaw YF, Chang TT, Guan R, Tai DI, Ng KY, et al. Lamivudine (100 mg qd) for 1 year significantly improves necroinflammatory activity and reduces progression in fibrosis stage: Results of a placebo-controlled multicenter study in Asia of lamivudine for chronic hepatitis B infection [Abstract]. Hepatology 1997; 26(Suppl):357A.